

Pierre Ernst

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2386493/publications.pdf>

Version: 2024-02-01

87
papers

4,387
citations

136950
32
h-index

106344
65
g-index

87
all docs

87
docs citations

87
times ranked

4340
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple Inhaler versus Dual Bronchodilator Therapy in COPD: Real-World Effectiveness on Mortality. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2022, 19, 1-9.	1.6	19
2	Fluticasone-Based versus Budesonide-Based Triple Therapies in COPD: Real-World Comparative Effectiveness and Safety. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2022, 19, 109-117.	1.6	3
3	Discontinuation of Inhaled Corticosteroids from Triple Therapy in COPD: Effects on Major Outcomes in Real World Clinical Practice. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2022, 19, 133-141.	1.6	4
4	A multifaceted intervention to improve asthma control via asthma education, medical follow-up and regular self-monitoring after pediatric emergency department visits for asthma. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 28-37.	0.5	0
5	Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 673-682.	0.8	31
6	Type 2 diabetes mellitus and risk of community-acquired pneumonia: a systematic review and meta-analysis of observational studies. CMAJ Open, 2021, 9, E62-E70.	2.4	14
7	SGLT â€2 inhibitors and the risk of hospitalization for communityâ€™acquired pneumonia: A populationâ€™based cohort study. Pharmacoepidemiology and Drug Safety, 2021, 30, 740-748.	1.9	6
8	Comparative Effectiveness of Initial LAMA versus LABA in COPD: Real-World Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 1-8.	1.6	11
9	Validity of an algorithm to identify cardiovascular deaths from administrative health records: a multi-database population-based cohort study. BMC Health Services Research, 2021, 21, 758.	2.2	8
10	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple populationâ€™based cohort studies. Pharmacoepidemiology and Drug Safety, 2021, 30, 1339-1352.	1.9	17
11	Regional variation in the potentially inappropriate first-line use of fluoroquinolones in Canada as a key to antibiotic stewardship? A drug utilization review study. BMC Infectious Diseases, 2021, 21, 733.	2.9	4
12	Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety. Respiratory Medicine, 2021, 189, 106645.	2.9	7
13	Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study. Rheumatology, 2020, 59, 820-827.	1.9	5
14	Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD. Chest, 2020, 157, 846-855.	0.8	57
15	Inhaled corticosteroid use and the incidence of lung cancer in COPD. European Respiratory Journal, 2020, 55, 1901720.	6.7	18
16	Response. Chest, 2020, 158, 832-833.	0.8	0
17	Sodiumâ€™Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis. Annals of Internal Medicine, 2020, 173, 417-425.	3.9	97
18	Sodiumâ€™Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study. Diabetes Care, 2020, 43, 2444-2452.	8.6	26

#	ARTICLE	IF	CITATIONS
19	Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ, The, 2020, 370, m3342.	6.0	70
20	Response. Chest, 2020, 157, 1395-1396.	0.8	0
21	Sodium-glucose co-transporter 2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study. Diabetes, Obesity and Metabolism, 2020, 22, 1648-1658.	4.4	13
22	Avoiding immortal time bias in observational studies. European Respiratory Journal, 2020, 55, 2000138.	6.7	5
23	Response. Chest, 2020, 157, 1045-1046.	0.8	0
24	Response. Chest, 2019, 156, 416-417.	0.8	0
25	Comparative safety of abatacept in rheumatoid arthritis with COPD: A real-world population-based observational study. Seminars in Arthritis and Rheumatism, 2019, 49, 366-372.	3.4	12
26	Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice. Chest, 2019, 155, 1158-1165.	0.8	58
27	Comparative Effectiveness Of Fluoroquinolone Antibiotic Use In Uncomplicated Acute Exacerbations Of COPD: A Multi-Cohort Study. International Journal of COPD, 2019, Volume 14, 2939-2946.	2.3	5
28	Observational Studies of Inhaled Corticosteroid Effectiveness in COPD. Chest, 2018, 154, 257-265.	0.8	23
29	Long-term Use of Inhaled Corticosteroids in COPD and the Risk of Fracture. Chest, 2018, 153, 321-328.	0.8	55
30	Beta-Blockers in COPD: A Methodological Review of the Observational Studies. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 520-525.	1.6	10
31	Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respiratory Medicine, the, 2018, 6, 855-862.	10.7	79
32	Blood eosinophils in COPD and the future risk of pneumonia. European Respiratory Journal, 2018, 52, 1800981.	6.7	9
33	Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. British Journal of Clinical Pharmacology, 2017, 83, 2077-2086.	2.4	45
34	Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia. Thorax, 2017, 72, 596.1-597.	5.6	8
35	Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events. European Respiratory Journal, 2017, 49, 1602245.	6.7	65
36	The Risk of Sepsis with Inhaled and Oral Corticosteroids in Patients with COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2017, 14, 137-142.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Statin potency and the risk of hospitalization for community-acquired pneumonia. British Journal of Clinical Pharmacology, 2017, 83, 1319-1327.	2.4	9
38	Enablers and determinants of the provision of written action plans to patients with asthma: a stratified survey of Canadian physicians. Npj Primary Care Respiratory Medicine, 2017, 27, 21.	2.6	23
39	Precision Medicine Urgency. Chest, 2017, 152, 227-231.	0.8	29
40	Physician agreement regarding the expansion of pharmacist professional activities in the management of patients with asthma. International Journal of Pharmacy Practice, 2017, 25, 335-342.	0.6	5
41	Long-Acting Bronchodilator Initiation in COPD and the Risk of Adverse Cardiopulmonary Events. Chest, 2017, 151, 60-67.	0.8	41
42	The effect of statins on influenza-like illness morbidity and mortality. Pharmacoepidemiology and Drug Safety, 2017, 26, 63-70.	1.9	17
43	Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study. BMJ: British Medical Journal, 2017, 359, j4323.	2.3	77
44	Enablers of Physician Prescription of a Long-Term Asthma Controller in Patients with Persistent Asthma. Canadian Respiratory Journal, 2016, 2016, 1-9.	1.6	5
45	Confounding by drug formulary restriction in pharmacoepidemiologic research. Pharmacoepidemiology and Drug Safety, 2016, 25, 278-286.	1.9	6
46	Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease. British Journal of Clinical Pharmacology, 2016, 82, 461-472.	2.4	35
47	The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations. European Respiratory Journal, 2016, 47, 344-345.	6.7	3
48	A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. New England Journal of Medicine, 2016, 374, 1145-1154.	27.0	191
49	Inflammatory bowel disease and risk of mortality in COPD. European Respiratory Journal, 2016, 47, 1357-1364.	6.7	29
50	Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ, The, 2016, 352, i581.	6.0	78
51	The Effectiveness of Web-Based Asthma Self-Management System, My Asthma Portal (MAP): A Pilot Randomized Controlled Trial. Journal of Medical Internet Research, 2016, 18, e313.	4.3	59
52	Phenotypic Heterogeneity of Potentially Curable Non-Small-Cell Lung Cancer: Cohort Study with Cluster Analysis. Journal of Thoracic Oncology, 2015, 10, 754-761.	1.1	9
53	Tailoring interventions: identifying predictors of poor asthma control. Annals of Allergy, Asthma and Immunology, 2015, 114, 485-491.e1.	1.0	3
54	Discontinuation of Inhaled Corticosteroids in COPD and the Risk Reduction of Pneumonia. Chest, 2015, 148, 1177-1183.	0.8	68

#	ARTICLE	IF	CITATIONS
55	The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis. Thorax, 2015, 70, 508-510.	5.6	14
56	Inhaled corticosteroids in COPD: the clinical evidence. European Respiratory Journal, 2015, 45, 525-537.	6.7	148
57	Long-Acting β_2 -Agonists With vs Without Inhaled Corticosteroids for COPD. JAMA - Journal of the American Medical Association, 2015, 313, 305.	7.4	2
58	Patients' perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy. BMC Pulmonary Medicine, 2015, 15, 42.	2.0	63
59	Evaluating the impact of an integrated computer-based decision support with person-centered analytics for the management of asthma in primary care: a randomized controlled trial. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 773-783.	4.4	26
60	Increased incidence of inflammatory bowel disease in Québec residents with airway diseases. European Respiratory Journal, 2015, 45, 962-968.	6.7	50
61	Friday and weekend hospital stays: effects on mortality. European Respiratory Journal, 2014, 44, 627-633.	6.7	14
62	Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax, 2013, 68, 1029-1036.	5.6	383
63	Educating the Adolescent and Young Adult With Cystic Fibrosis About Their Reproductive Risks and Options: Response. Chest, 2013, 143, 580.	0.8	1
64	Systemic effects of inhaled corticosteroids. Current Opinion in Pulmonary Medicine, 2012, 18, 85-89.	2.6	36
65	Bronchodilator Use and the Risk of Arrhythmia in COPD. Chest, 2012, 142, 298-304.	0.8	49
66	Bronchodilator Use and the Risk of Arrhythmia in COPD. Chest, 2012, 142, 305-311.	0.8	87
67	Pramipexole use and the risk of pneumonia. BMC Neurology, 2012, 12, 113.	1.8	5
68	CNODES: the Canadian Network for Observational Drug Effect Studies. Open Medicine, 2012, 6, e134-40.	1.5	52
69	Risk of herpes zoster in patients prescribed inhaled corticosteroids: a cohort study. BMC Pulmonary Medicine, 2011, 11, 59.	2.0	16
70	Effect of a web-based chronic disease management system on asthma control and health-related quality of life: study protocol for a randomized controlled trial. Trials, 2011, 12, 260.	1.6	27
71	The Asthma Quiz for Kidz: A Validated Tool to Appreciate the Level of Asthma Control in Children. Canadian Respiratory Journal, 2004, 11, 541-546.	1.6	34
72	What Is New Since the Last (1999) Canadian Asthma Consensus Guidelines?. Canadian Respiratory Journal, 2001, 8, 5A-27A.	1.6	73

#	ARTICLE	IF	CITATIONS
73	Control of Asthma in Canada: Failure to Achieve Guideline Targets. Canadian Respiratory Journal, 2001, 8, 35A-40A.	1.6	124
74	Prostaglandin H Synthase 2 Expression in Airway Cells from Patients with Asthma and Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 636-640.	5.6	84
75	Inhaled Drug Delivery: A Practical Guide to Prescribing Inhaler Devices. Canadian Respiratory Journal, 1998, 5, 180-183.	1.6	23
76	Increased Expression of Interleukin-16 in Bronchial Mucosa of Subjects with Atopic Asthma. American Journal of Respiratory Cell and Molecular Biology, 1997, 17, 193-202.	2.9	141
77	Birthweight and Preterm Birth in Relation to Indicators of Childhood Asthma. Canadian Respiratory Journal, 1997, 4, 91-97.	1.6	8
78	Use of Oral Xanthines in the Elderly and Extent of "Silent Risks": Information from a Drug Dispensing Database. , 1997, 6, 135-136.		0
79	Confounding by Indication and Channeling over Time: The Risks of β_2 -Agonists. American Journal of Epidemiology, 1996, 144, 1161-1169.	3.4	100
80	Increased morbidity and mortality related to asthma among asthmatic patients who use major tranquilisers. BMJ: British Medical Journal, 1996, 312, 79-81.	2.3	63
81	What Is the Role of Beta-Agonist Bronchodilators in the Day-to-Day Treatment of Chronic Asthma?. Canadian Respiratory Journal, 1995, 2, 32A-34A.	1.6	0
82	The Use of β_2 -Agonists and the Risk of Death and near Death from Asthma. New England Journal of Medicine, 1992, 326, 501-506.	27.0	1,228
83	Fenoterol and death from asthma. Medical Journal of Australia, 1992, 157, 567-568.	1.7	2
84	Fissural thickening and exposure to asbestos: Occurrence, determinants, and functional impact. American Journal of Industrial Medicine, 1991, 20, 785-793.	2.1	3
85	Relationship of lung geometry to the development of pleural abnormalities in insulation workers exposed to asbestos. American Journal of Industrial Medicine, 1989, 15, 417-425.	2.1	3
86	Obstructive and restrictive ventilatory impairment in polyvinylchloride fabrication workers. American Journal of Industrial Medicine, 1988, 14, 273-279.	2.1	10
87	Between- and within-reader variability in the assessment of pleural abnormality using the ILO 1980 international classification of pneumoconioses. American Journal of Industrial Medicine, 1988, 14, 537-543.	2.1	32